Soft tissue sarcoma market is expected to grow USD 2,300 Million at a CAGR 10.5% during the forecast period 2022-2030.
Soft Tissue Sarcoma Market Scenario
The Soft Tissue Sarcoma Market is anticipated to reach USD 2,300 Million by 2030 at 10.5% CAGR during the forecast period 2022-2030.Soft tissue sarcoma is a type of cancer that develops from tissues such as nerves, muscles, fats, blood vessels and deep skin tissues. Generally occuring in the muscles, tissues, and blood vessels that protect, support and surround the organs. Moreover, it is not categorized as tumor, but can be life-threatening if the cancer spreads to other parts of the body. There are around 50 different types of soft tissue sarcoma, such as adult fibrosarcoma, angiosarcoma, clear cell sarcoma, alveolar soft-part sarcoma, kaposi sarcoma, malignant mesenchymoma, rhabdomyosarcoma, and others.
Currently, there are very few products approved for the treatment of soft tissue sarcoma. For instance, in October 2016, U.S. Food and Drug Administration issued an accelerated approval notice for Eli Lilly and Company’s drug Lartruvo (Olaratumab) with Doxorubicin to treat certain types soft tissue carcinoma. Some of the drugs used for the treatment of soft tissue sarcoma include trabectedin (yondelis), sunitinib (sutent), sirolimus (rapamune), and doxorubicin (adriamycin), bevacizumab (avastin), and others.
Increase in the incidence and prevalence of different types of cancers, rising cases of soft tissue sarcoma, increasing R&D activities on drugs and other therapies, patent expiry of branded drugs, are some of the factors fuelling the growth of the soft tissue sarcoma market over the forecast period. However, stringent regulatory guidelines, adverse side effects of the treatment, and high cost for the radiotherapy and chemotherapy may hinder the growth of soft tissue sarcoma treatment market over the forecast period.
The methods for diagnosis of soft tissue sarcoma include some physical examination such as X-ray imaging, CT scan, MRI, ultrasound, PET scan and a biopsy. Such examinations in conjugation with other tests are important to plan a suitable treatment method for this condition.
Soft Tissue Sarcoma Market Segmentation
The soft tissue sarcoma market is segmented on the basis of treatment, disease type, distribution channel, and end-users.
On the basis of the treatment type, the soft tissue sarcoma treatment market is segmented into targeted therapy, chemotherapy, anti-angiogenesis drugs, radiation therapy. Furthermore, the radiation therapy is subcatergorized into internal radiation therapy and external radiation therapy.
On the basis of the disease type, soft tissue sarcoma treatment market is segmented into local sarcoma, regional sarcoma, and metastatic sarcoma
On the basis of the distribution channel, soft tissue sarcoma treatment market is segmented into hospital pharmacies, retail pharmacies and others.
On the basis of the end user, the global soft tissue sarcoma treatment market has been segmented into hospitals, oncology centers, and long term care centers.
Soft Tissue Sarcoma Market- Key Players
Some of key the players in the global soft tissue sarcoma market are GlaxoSmithKline plc (U.K), Eli Lilly and Company (U.S.), Pfizer, Inc. (U.S.), Bristol-Myers Squibb (U.S.), F. Hoffmann-La Roche AG (Genentech) (Switzerland), Johnson & Johnson Services, Inc. (U.S.), Teva Pharmaceutical Industries Ltd (Israel), and Celgene Corporation (U.S.) and others.
Various key players are active in the soft tissue sarcoma treatment market in terms of product launches, research, and development activities. For instance, in 2012, Threshold Pharmaceuticals Inc. signed a global license agreement for Evofosfamide, which is the most advanced first-line drug for soft tissue sarcoma with Merck KGaA. GSK’s Votrient (pazopanib) is approved for second-line treatment, and another drug Aldoxorubicin is approved as first-line drug for the treatment of soft tissue sarcoma. Currently, doxorubicin is commonly used for the treatment of soft tissue sarcoma.
Research Methodology Sources: Annual reports, Press release, White paper, and Company presentation
Soft Tissue Sarcoma Market Regional Analysis
The global soft tissue sarcoma market consists of countries namely America, Europe, Asia Pacific, and the Middle East & Africa.
The Americas soft tissue sarcoma market is projected to hold the largest share of the global soft tissue sarcoma market. Moreover, North America dominated the overall market in terms of revenue in 2016. According to American Cancer Society, approximately 12,390 people in 2016 were believed to suffer from soft tissue sarcoma and related cancer. High incidence rate of soft tissue sarcomas, increase in awareness about this condition, rise in focus on healthcare, and well-established healthcare infrastructure are some of the factors driving the market in North America.
Europe holds a key share in soft tissue sarcoma treatment market attributed to change in lifestyle, increase in R&D activities for the development of new drugs. The European soft tissue sarcoma market is expected to have a tremendous growth during the forecast period.
The market in Asia Pacific is estimated to expand at a high CAGR during the forecast period, led by an increase in government spending on healthcare services in India and China. The Middle East & Africa is projected to expand during the forecast period, owing to the rise in investments by market players and increase in prevalence of soft tissue sarcomas.
Soft Tissue Sarcoma Drug Suppliers
Soft Tissue Sarcoma Drug Manufacturers
Research and Development (R&D) Companies
Medical Research Laboratories
Academic Medical Institutes and Universities
|Market Size||USD 2,300 Million|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Type, distribution channel, and end-users|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||GlaxoSmithKline plc (U.K), Eli Lilly and Company (U.S.), Pfizer, Inc. (U.S.), Bristol-Myers Squibb (U.S.), F. Hoffmann-La Roche AG (Genentech) (Switzerland), Johnson & Johnson Services, Inc. (U.S.), Teva Pharmaceutical Industries Ltd (Israel), and Celgene Corporation (U.S.) and others|
|Key Market Opportunities||Research and Development|
|Key Market Drivers||
The outlook of the global soft tissue sarcoma market looks extremely promising.
The global soft tissue sarcoma market is projected to grow at approximately 10.5% CAGR during forecast period (2022-2030).
Rising prevalence of soft tissue sarcoma.
North America holds the largest share in the global soft tissue sarcoma market followed by Europe and Asia Pacific, respectively.
Eli Lilly and Company (US), GlaxoSmithKline plc. (UK), Pfizer, Inc. (US), F. Hoffmann-La Roche AG (Switzerland), Bristol-Myers Squibb (US), Johnson & Johnson Services, Inc. (US), Celgene Corporation (US), and Teva Pharmaceutical Industries Ltd (Israel), are some of the major players operating in the soft tissue sarcoma market.